Business

The news of an $85 million shortfall between what partner banks of Synapse are holding and what depositors are owed has sent shockwaves throughout the fintech sector. Customers who trusted fintech firms that utilized Synapse to connect with banks are now facing the harsh reality that their balances may not be as secure as they
0 Comments
The Food and Drug Administration has recently extended its approval of GSK’s respiratory syncytial virus vaccine to include adults between the ages of 50 to 59 who are at higher risk of contracting severe illness from the virus. This vaccine, called Arexvy, is the first of its kind to be authorized by the FDA for
0 Comments
Lululemon, a popular athletic apparel retailer, recently reported flat comparable sales in the Americas, its largest market. Despite beating Wall Street’s earnings estimates, the company only narrowly topped revenue expectations. The company’s full fiscal year guidance suggests that it is optimistic about conditions improving in the back half of the year. In the first fiscal
0 Comments
Paramount Global’s current leadership team recently presented a go-forward plan at the company’s annual shareholder meeting, outlining strategic priorities in case a sale of the company does not materialize. The presentation, led by CBS CEO George Cheeks, Paramount Media Networks CEO Chris McCarthy, and Paramount Pictures CEO Brian Robbins, focused on key initiatives such as
0 Comments
After weeks of discussions and negotiations, Paramount and Skydance have finally agreed to terms of a merger. This deal, reported by CNBC’s David Faber, could potentially be announced in the coming days pending signoff from Paramount’s controlling shareholder, Shari Redstone. The agreement involves a consortium led by David Ellison’s Skydance, supported by private equity firms
0 Comments
The Food and Drug Administration recently approved Moderna’s vaccine for respiratory syncytial virus (RSV) for adults ages 60 and above. This marks a significant milestone for Moderna as it seeks to diversify its product portfolio beyond its Covid jab. The approval is based on a late-stage trial that demonstrated the vaccine’s efficacy in older adults,
0 Comments